Myriad Genetics/$MYGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Myriad Genetics
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Ticker
$MYGN
Sector
Primary listing
Employees
2,700
Headquarters
Website
Myriad Genetics Metrics
BasicAdvanced
$570m
-
-$4.29
1.81
-
Price and volume
Market cap
$570m
Beta
1.81
52-week high
$8.59
52-week low
$3.53
Average daily volume
1.6m
Financial strength
Current ratio
2.402
Quick ratio
1.906
Long term debt to equity
60.581
Total debt to equity
62.685
Interest coverage (TTM)
-4.64%
Profitability
EBITDA (TTM)
-12.3
Gross margin (TTM)
69.93%
Net profit margin (TTM)
-48.24%
Operating margin (TTM)
-7.73%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-4.77%
Return on equity (TTM)
-76.73%
Valuation
Price to revenue (TTM)
0.679
Price to book
1.69
Price to tangible book (TTM)
3.94
Price to free cash flow (TTM)
-24.258
Free cash flow yield (TTM)
-4.12%
Free cash flow per share (TTM)
-0.249
Growth
Revenue change (TTM)
-0.28%
Earnings per share change (TTM)
283.65%
3-year revenue growth (CAGR)
6.07%
3-year earnings per share growth (CAGR)
33.42%
What the Analysts think about Myriad Genetics
Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.
Myriad Genetics Financial Performance
Revenues and expenses
Myriad Genetics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.